Central nervous system (CNS) progression was reduced with osimertinib plus chemotherapy for patients with EGFR-mutated non-small cell lung cancer plus CNS metastases.
Darlene Dobkowski, MA
Advertisement
Articles by Darlene Dobkowski, MA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
New Survey Highlights Quality-of-Life Benefits of Dry Eye Disease Treatment
2
AI Chatbots Score Below 28% on Colorectal Cancer Questions
3
Team-Based Telehealth Model Matches In-Person Care for Atopic Dermatitis
4
5 Notable FDA Approvals From the First Half of 2026
5